SERIES A WARRANT COMMON STOCK PURCHASE WARRANT PHARMACYTE BIOTECH, INC.Warrant Agreement • August 23rd, 2021 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
THIS SERIES A WARRANT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 24, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT PHARMACYTE BIOTECH, INC.Pre-Funded Common Stock Purchase Warrant • August 23rd, 2021 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 23rd, 2021 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 19, 2021, between PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Placement Agent Common Stock Purchase Warrant PHARMACYTE BIOTECH, INC.Placement Agent Common Stock Agreement • August 23rd, 2021 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
This Placement Agent Common Stock Purchase Warrant (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 19, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC (“Wainwright”), dated as of April 26, 2021 (the “Engagement Agreement”)
